Home Nav
Nextech Invest Logo

Thilo Schroeder

Alfred Scheidegger

Thilo Schroeder, Ph.D. is Partner at Nextech Invest Ltd., a global venture fund focused on investing in leading oncology companies. Prior to joining Nextech Invest in 2012, Dr. Schroeder worked in research specializing on the development of Designed Ankyrin Repeat Proteins (DARPins) as specific protein inhibitors (licensed to Molecular Partners / SWX:MOLN). He acquired expertise in molecular biology as an Intern at Micromet Ltd. (now Amgen) and during his studies at the University of Sydney. Dr. Schroeder currently serves as board member of Revolution Medicines, IDEAYA Bioscience, ImaginAb and board observer of Peloton Therapeutics. He is a prior board member of Blueprint Medicines (NASDAQ:BPMC), SiROP Global, and board observer of Tracon Pharmaceuticals (NASDAQ:TCON). He holds a Ph.D. in biochemistry from the University of Zurich in Switzerland, a M.Sc. in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the Technical University of Darmstadt in Germany.

Mr. Schroeder is responsible for the following Nextech portfolio companies:

Peloton Therapeutics, Kura Oncology, ImaginAb, Blueprint Medicines

 

19TH ANNUAL BIO€QUITY EUROPE

14.05. – 16.05.2018

Ghent, Belgium

  • 07.08.2018

    Kura Oncology to present at 2018 Wedbush PacGrow healthcare...

  • 06.08.2018

    Kura Oncology reports second quarter 2018 financial...

  • 06.08.2018

    Neon Therapeutics reports second quarter 2018 financial...

Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close